Cefiderocol, a novel siderophore cephalosporin in late-stage clinical development, utilizes a "Trojan horse" active transport mechanism to enter bacteria and has proven in vitro activity against carbapenem-resistant gram-negative pathogens, including those with major carbapenem-resistance mechanisms, and stability against all carbapenemases.
No takes yet. Share an insight, caveat, or question.
Robert A. Bonomo (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: